The demands on market access teams are growing rapidly as the specific needs of key stakeholders grow ever greater. How do you structure and manage your market access team for best results and evaluate their...

Oncology Market Access Europe – Payer and Industry Perspectives answers your questions:
What are payers looking for when making decisions regarding oncology reimbursement?
How are HTAs and other challenges...

Faced with slipping or negligible GDP growth and an economic crisis, Eurozone countries are drilling down into healthcare budgets as a means of controlling expenditure.
From price cuts, tighter reimbursement criteria...

Two recessions in a decade, financial austerity, and unprecedented pressure to prove product value to all stakeholders. There is no question that the pharma game has changed in the new “Outcomes Era”, in...

Once, they were the benchmark for product development. But these days, randomised controlled trials (RCTs) are simply a starting point—and a starting point under pressure to carry even more value.
As notions of...

Their development costs can be high and the market is relative small, yet orphan drugs represent a significant contribution to public health—and the pharmaceutical market.
In fact, analysts predict that orphan...

There’s a revolution happening...and it’s going to change the way pharma thinks.
As the accountable care movement gains traction in the United States and physicians eye a possible $1 trillion in saved...

Times, they are a-changin’—at least for the American biological product market.
With five major biological products worth a collective US$35 billion in annual sales now facing imminent patent expiration, the...

Ten provinces. Three territories. Three layers of government. And pharmaceutical spending of C$33 billion a year.
Over the next five years, the International Monetary Fund estimates that Canada’s growth with...

The sustained and challenging economic environment in the EU has impacted – and is impacting - pharmaceutical companies as never before. But success is still possible for those that understand the new operating...

CCG commissioners want pharma?s money and expertise but on their terms ? how do you develop effective Joint Working partnerships which meet everyone?s objectives?
On April 1, 2013, the NHS in England underwent profound...

At last – a practical guide to building your Health Outcome Liaison team and developing an effective HOL strategy.
This comprehensive report explains what is driving the rise of HOLs globally, and provides...

Changes in the healthcare landscape have put payers (public and private) under mounting pressure to reduce the cost of care, and given them much greater influence over market access to new medicines.
In this new...